A systematic literature review of MTAP deletions in solid and hematologic Cancers
Background: Methylthioadenosine phosphorylase (MTAP) deficiency is observed across multiple cancers and represents an emerging biomarker with therapeutic potential via synthetic lethality with PRMT5 inhibition. This systematic literature review summarizes the prevalence of MTAP deletions or loss of...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294225001029 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849245759315116032 |
|---|---|
| author | Mary C. Clouser Mina Suh Naimisha Movva Janet S. Hildebrand Susan T. Pastula Martina Schoehl Antreas Hindoyan Akhila Balasubramanian Jon P. Fryzek Soo-Ryum Yang |
| author_facet | Mary C. Clouser Mina Suh Naimisha Movva Janet S. Hildebrand Susan T. Pastula Martina Schoehl Antreas Hindoyan Akhila Balasubramanian Jon P. Fryzek Soo-Ryum Yang |
| author_sort | Mary C. Clouser |
| collection | DOAJ |
| description | Background: Methylthioadenosine phosphorylase (MTAP) deficiency is observed across multiple cancers and represents an emerging biomarker with therapeutic potential via synthetic lethality with PRMT5 inhibition. This systematic literature review summarizes the prevalence of MTAP deletions or loss of expression and prognostic impacts of MTAP deletions or loss in adult and pediatric patients with specific solid or hematologic cancers. Methods: Following PRISMA methodology, the literature on MTAP deletion or loss in multiple cancer types was reviewed. Prevalence, laboratory testing methods, patient characteristics, and clinical outcomes according to MTAP status were synthesized. Study quality was determined using standard tools. Results: Of the 352 identified studies, 37 reported on MTAP. The majority were retrospective cohorts (N=32; 86%). The most common laboratory test type was NGS, specifically FoundationOne (N=7, 24%). MTAP deletion (loss) prevalence varied across tumor types and were generally lowest in gastric cancer (4%–14%) and highest in glioblastoma (26%–60%). MTAP deletion was correlated with higher prevalence of KRAS. Variation by age, gender, and race/ethnicity were inconsistently reported. Survival outcomes were reported most often for GBM and NSCLC with some studies suggesting worse overall survival among patients with MTAP deletions, although the evidence was heterogeneous. Conclusion: This is the first systematic review to summarize the literature on MTAP deletions or loss of expression across several solid and hematologic cancers. MTAP deletions and/or loss of expression occur in many cancer types, presenting a promising target for pan-cancer therapy. |
| format | Article |
| id | doaj-art-ede2a30de3bf48efbdbbd18499759d24 |
| institution | Kabale University |
| issn | 2468-2942 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj-art-ede2a30de3bf48efbdbbd18499759d242025-08-20T03:58:41ZengElsevierCancer Treatment and Research Communications2468-29422025-01-014410096610.1016/j.ctarc.2025.100966A systematic literature review of MTAP deletions in solid and hematologic CancersMary C. Clouser0Mina Suh1Naimisha Movva2Janet S. Hildebrand3Susan T. Pastula4Martina Schoehl5Antreas Hindoyan6Akhila Balasubramanian7Jon P. Fryzek8Soo-Ryum Yang9Amgen, Thousand Oaks, CA, USA; Corresponding author at: One Amgen Center Drive, Mail Stop: 38-4-B, Thousand Oaks, CA 91320-1799.EpidStrategies, A Division of ToxStrategies, LLC, Mission Viejo, CA, USAEpidStrategies, A Division of ToxStrategies, LLC, Mission Viejo, CA, USAAmgen, Thousand Oaks, CA, USAEpidStrategies, A Division of ToxStrategies, LLC, Mission Viejo, CA, USAAmgen, Thousand Oaks, CA, USAAmgen, Thousand Oaks, CA, USAAmgen, Thousand Oaks, CA, USAEmployee of EpidStrategies at the time of study conduct, USAMemorial Sloan Kettering Cancer Center, New York, NY, USABackground: Methylthioadenosine phosphorylase (MTAP) deficiency is observed across multiple cancers and represents an emerging biomarker with therapeutic potential via synthetic lethality with PRMT5 inhibition. This systematic literature review summarizes the prevalence of MTAP deletions or loss of expression and prognostic impacts of MTAP deletions or loss in adult and pediatric patients with specific solid or hematologic cancers. Methods: Following PRISMA methodology, the literature on MTAP deletion or loss in multiple cancer types was reviewed. Prevalence, laboratory testing methods, patient characteristics, and clinical outcomes according to MTAP status were synthesized. Study quality was determined using standard tools. Results: Of the 352 identified studies, 37 reported on MTAP. The majority were retrospective cohorts (N=32; 86%). The most common laboratory test type was NGS, specifically FoundationOne (N=7, 24%). MTAP deletion (loss) prevalence varied across tumor types and were generally lowest in gastric cancer (4%–14%) and highest in glioblastoma (26%–60%). MTAP deletion was correlated with higher prevalence of KRAS. Variation by age, gender, and race/ethnicity were inconsistently reported. Survival outcomes were reported most often for GBM and NSCLC with some studies suggesting worse overall survival among patients with MTAP deletions, although the evidence was heterogeneous. Conclusion: This is the first systematic review to summarize the literature on MTAP deletions or loss of expression across several solid and hematologic cancers. MTAP deletions and/or loss of expression occur in many cancer types, presenting a promising target for pan-cancer therapy.http://www.sciencedirect.com/science/article/pii/S2468294225001029CancerCDKN2ACo-mutationsHomozygous deletionsMTAPSurvival |
| spellingShingle | Mary C. Clouser Mina Suh Naimisha Movva Janet S. Hildebrand Susan T. Pastula Martina Schoehl Antreas Hindoyan Akhila Balasubramanian Jon P. Fryzek Soo-Ryum Yang A systematic literature review of MTAP deletions in solid and hematologic Cancers Cancer Treatment and Research Communications Cancer CDKN2A Co-mutations Homozygous deletions MTAP Survival |
| title | A systematic literature review of MTAP deletions in solid and hematologic Cancers |
| title_full | A systematic literature review of MTAP deletions in solid and hematologic Cancers |
| title_fullStr | A systematic literature review of MTAP deletions in solid and hematologic Cancers |
| title_full_unstemmed | A systematic literature review of MTAP deletions in solid and hematologic Cancers |
| title_short | A systematic literature review of MTAP deletions in solid and hematologic Cancers |
| title_sort | systematic literature review of mtap deletions in solid and hematologic cancers |
| topic | Cancer CDKN2A Co-mutations Homozygous deletions MTAP Survival |
| url | http://www.sciencedirect.com/science/article/pii/S2468294225001029 |
| work_keys_str_mv | AT marycclouser asystematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT minasuh asystematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT naimishamovva asystematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT janetshildebrand asystematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT susantpastula asystematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT martinaschoehl asystematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT antreashindoyan asystematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT akhilabalasubramanian asystematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT jonpfryzek asystematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT sooryumyang asystematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT marycclouser systematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT minasuh systematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT naimishamovva systematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT janetshildebrand systematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT susantpastula systematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT martinaschoehl systematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT antreashindoyan systematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT akhilabalasubramanian systematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT jonpfryzek systematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers AT sooryumyang systematicliteraturereviewofmtapdeletionsinsolidandhematologiccancers |